bioMerieux SA BIM
EURONEXT · France · Health Technology
€77.20-0.55 (-0.71%)
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · EUR · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
BioMerieux SA (BMXMF) reports robust free cash flow growth and strategic product launches, while navigating regional market fluctuations and competitive pressures.
bioMérieux, a world leader in the field of in vitro diagnostics, today introduces the launch of GENE-UP® TYPER SLM, a new real-time PCR solution supporting rapid root cause analysis by discriminating Salmonella in the food industry environments.
The Saudi Arabia in vitro diagnostics (IVD) market is set for steady growth, driven by the increasing prevalence of chronic and infectious diseases and enhanced healthcare spending. Estimated to rise from US$ 820.36 million in 2025 to US$ 1.17 billion by 2034, the market is supported by technological advancements, governmental investments under Vision 2030, and a strong focus on early disease detection. Adoption of molecular diagnostics and automated systems is anticipated to fuel market demand,
BioMerieux SA (BMXMF) reports robust financial results with significant growth in cash flow and strategic expansions in its BIOFIRE and SPOTFIRE systems.
bioMérieux’s latest analyst update keeps the Fair Value target steady at €119.12, even as underlying model inputs such as the discount rate and revenue assumptions are fine tuned. Both bullish and bearish analysts link this stable headline target, including the recent €3 trimming of some price objectives, to a more balanced view of risk, growth, and profitability around the diagnostics franchise. As you read on, you will see how to track these subtle shifts and what they might mean for your...
Dublin, Oct. 21, 2025 (GLOBE NEWSWIRE) -- The "bioMerieux SA (BIM) - Product Pipeline Analysis, 2025 Update" has been added to ResearchAndMarkets.com's offering. This report is an invaluable resource, providing data, thorough analysis, and actionable insights so stakeholders can critically assess bioMerieux's pipeline products. It offers detailed information about the company, its primary products, and notable brands. These insights are geared to enhance strategic decision-making processes and f
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.